pravastatin has been researched along with ritonavir in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 17 (70.83) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Ammassari, A; Baldini, F; Cingolani, A; De Luca, A; Di Giambenedetto, S; Murri, R | 1 |
| Aberg, JA; Alston, B; Aweeka, F; Blaschke, T; Fang, F; Fichtenbaum, CJ; Gerber, JG; Kosel, B; Rosenkranz, SL; Segal, Y | 1 |
| Piliero, PJ | 1 |
| Gaughan, JP; Klibanov, OM; Tedaldi, EM; van den Berg-Wolf, M | 1 |
| Cope, D; Iskander, E; Mikhail, N | 1 |
| Bloch, M; Calmy, A; Carr, A; Cooper, DA; Delhumeau, C; Finlayson, R; Hirschel, B; Norris, R; Rafferty, M; Wand, H | 1 |
| Auclair, M; Bastard, JP; Boccara, F; Capeau, J; Caron-Debarle, M; Lefèvre, C; Vigouroux, C | 1 |
| Aslangul, E; Assoumou, LK; Bastard, JP; Capeau, J; Costagliola, D; Fellahi, S | 1 |
| Aberg, JA; Evans, SE; Fichtenbaum, CJ | 1 |
| Anderson, PL; Aquilante, CL; Christians, U; Daily, EB; Hoffman, KL; Hopley, CW; Kiser, JJ; Kosmiski, LA; Predhomme, JA; Schniedewind, B; Sidhom, MS | 1 |
| Aslangul, E; Assoumou, L; Bittar, R; Bonnefont-Rousselot, D; Cherfils, C; Costagliola, D; Federspiel, MC; Giral, P; Kalmykova, O; Valantin, MA | 1 |
| Banba, H; Takayama, K; Takeda-Morishita, M; Tomaru, A | 1 |
| Ando, Y; Deguchi, M; Hirota, T; Ieiri, I; Irie, S; Izumi, N; Kanda, E; Kimura, M; Kotani, N; Kusuhara, H; Maeda, K; Matsuguma, K; Matsuki, S; Morishita, M; Okuzono, T; Sugiyama, Y; Tsunemitsu, S; Yamane, N | 1 |
| Afonso, P; Auclair, M; Capeau, J; Capel, E; Caron-Debarle, M | 1 |
2 review(s) available for pravastatin and ritonavir
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 trial(s) available for pravastatin and ritonavir
| Article | Year |
|---|---|
Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study.
Topics: Adult; Anticholesteremic Agents; Drug Tolerance; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hyperlipidemias; Indinavir; Male; Nelfinavir; Pilot Projects; Pravastatin; Ritonavir; Saquinavir; Treatment Outcome | 2000 |
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Drug Interactions; Heptanoic Acids; HIV Protease Inhibitors; HIV Seronegativity; Human Experimentation; Humans; Pravastatin; Pyrroles; Ritonavir; Saquinavir; Simvastatin | 2002 |
No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial.
Topics: Absorptiometry, Photon; Adiposity; Adult; Anti-Retroviral Agents; Anticholesteremic Agents; Dideoxynucleosides; Drug Therapy, Combination; Extremities; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Middle Aged; Pravastatin; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Uridine | 2010 |
Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin.
Topics: Adult; Cholesterol; Darunavir; Drug Interactions; Female; Haplotypes; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Genetic; Pravastatin; Ritonavir; Sulfonamides; Triglycerides | 2012 |
Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor.
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fluorobenzenes; France; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Ritonavir; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2012 |
Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromatography, Liquid; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; HIV Protease Inhibitors; Humans; Intestines; Liver; Liver-Specific Organic Anion Transporter 1; Male; Midazolam; Organic Anion Transporters; Pravastatin; Ritonavir; Saquinavir; Tandem Mass Spectrometry; Terfenadine; Young Adult | 2013 |
16 other study(ies) available for pravastatin and ritonavir
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Interaction between ritonavir and statins.
Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Drug Interactions; Heptanoic Acids; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Ritonavir; Simvastatin | 2002 |
Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients.
Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Azetidines; Cholesterol, LDL; Drug Administration Schedule; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Lopinavir; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Ritonavir; Treatment Outcome | 2008 |
Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Dyslipidemias; Emtricitabine; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oligopeptides; Organophosphonates; Pravastatin; Pyridines; Rhabdomyolysis; Ritonavir; Tenofovir | 2009 |
Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin.
Topics: Acetylcysteine; Adult; Antioxidants; Case-Control Studies; Cell Proliferation; Cells, Cultured; Cellular Senescence; Coronary Vessels; Cyclin-Dependent Kinase Inhibitor p21; Drug Therapy, Combination; Endothelial Cells; Farnesyltranstransferase; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lamin Type A; Lopinavir; Metalloporphyrins; Methionine; Middle Aged; Nuclear Proteins; Oxidative Stress; Paris; Pravastatin; Protein Precursors; Pyrimidinones; Ritonavir; Time Factors; Tumor Suppressor Protein p53 | 2010 |
High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors.
Topics: Anticholesteremic Agents; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Female; HIV Infections; Humans; Male; Middle Aged; Pravastatin; Ritonavir | 2011 |
High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection.
Topics: C-Reactive Protein; Cardiovascular Diseases; Dyslipidemias; Female; HIV Infections; Humans; Male; Pravastatin; Ritonavir | 2011 |
Analysis of the pharmacokinetic boosting effects of ritonavir on oral bioavailability of drugs in mice.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B; Biological Availability; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Interactions; Female; HIV Protease Inhibitors; Inactivation, Metabolic; Mice; Microsomes; Midazolam; Pravastatin; Ritonavir; Saquinavir; Terfenadine | 2013 |
Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Cellular Senescence; Darunavir; Drug Synergism; Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lopinavir; Nitric Oxide; Oligopeptides; Oxidative Stress; Pravastatin; Pyridines; Ritonavir; Sulfonamides | 2014 |